Bragar Eagel & Squire, P.C. Urgently Reminds Investors of RCI and Fortinet to Contact the Firm Regarding Upcoming Lead Plaintiff Deadlines

Bragar Eagel & Squire, P.C. Urgently Reminds Investors of RCI and Fortinet to Contact the Firm Regarding Upcoming Lead Plaintiff Deadlines GlobeNewswire November 19, 2025 NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf […]

Northrop Grumman Board Declares Quarterly Dividend

(NYSE:NOC), FALLS CHURCH, Va., Nov. 19, 2025 (GLOBE NEWSWIRE) — The board of directors of Northrop Grumman Corporation (NYSE: NOC) declared a quarterly dividend of $2.31 per share on Northrop Grumman common stock, payable December 17, 2025, to shareholders of record as of the close of business December 1, 2025. Northrop Grumman is a leading

Katahdin Bankshares Corp. Announces Quarterly Dividend

Katahdin Bankshares Corp. (OTCQX: KTHN), parent company of Katahdin Trust Company, announced that it has declared a cash dividend of $0.2025 per share for the fourth quarter of 2025. The dividend will be payable on December 22, 2025, to shareholders of record as of December 15, 2025. https://mma.prnewswire.com/media/2736310/Katahdin_Trust_Company_Logo.jpg This dividend represents a 15.7% increase over

MedStar Health Partners to Restore Wetlands on MedStar Harbor Hospital Campus

Project supports the Reimagine Middle Branch initiative, restores coastal ecosystem and improves water quality. MedStar Health has launched a major collaborative wetland restoration effort that is transforming more than 2,000 linear feet of degraded shoreline along the Middle Branch of the Patapsco River and reestablishes approximately seven acres of diverse coastal ecosystem. The MedStar Harbor

Northrop Grumman Board Declares Quarterly Dividend

Northrop Grumman Board Declares Quarterly Dividend GlobeNewswire November 19, 2025 FALLS CHURCH, Va., Nov. 19, 2025 (GLOBE NEWSWIRE) — The board of directors of Northrop Grumman Corporation (NYSE: NOC) declared a quarterly dividend of $2.31 per share on Northrop Grumman common stock, payable December 17, 2025, to shareholders of record as of the close of

Saudi-US Investment Deals Worth US $575 Billion to Reshape the Future Economy

— New investment agreements between Saudi and US companies inked in Washington D.C. amounting to US $267 billion — Figure comes on the back of government-to-government framework agreements announced at the White House. — Deals contribute to development of the Saudi Arabia & US economies, leveraging the competitive advantages of both countries — Partnerships span

Dallas KISS PR SEO Company Demonstrates How AI SEO WIth PR Achieves First-Page Google Rankings

Dallas, TX, Nov. 19, 2025 (GLOBE NEWSWIRE) — Dallas-based KISS PR has released a comprehensive guide revealing how artificial intelligence is transforming SEO strategies in 2025, with a focus on integrating strategic press release distribution to achieve first-page Google rankings. The resource outlines proven methodologies that combine AI-powered optimization with earned media placements to drive

Dallas KISS PR SEO Company Demonstrates How AI SEO WIth PR Achieves First-Page Google Rankings

Dallas KISS PR SEO Company Demonstrates How AI SEO WIth PR Achieves First-Page Google Rankings KISS PR has released a comprehensive 2025 guide outlining how combining AI-powered SEO with strategic press release distribution enables businesses to consistently achieve first-page Google rankings. GlobeNewswire November 19, 2025 Dallas, TX, Nov. 19, 2025 (GLOBE NEWSWIRE) — Dallas-based KISS

First US Bancshares, Inc. Announces Expansion of Share Repurchase Program

First USBancshares, Inc. (Nasdaq: FUSB) (the “Company”), a Delaware corporation based in Birmingham, Alabama, announced today that its Board of Directors has expanded the Company's existing share repurchase program. The Company has repurchased 1,389,972 shares of its common stock to date under the repurchase program, and 852,813 shares remain available for repurchase. The Board of

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase targets in cancer, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing its New

Scroll to Top